Research on the effectiveness of fulvestrant combined with trastuzumab on the human breast cancer cell line BT-474
Abstract：Objective To investigate the effectiveness of fulvestrant combined with trastuzumab on the human breast cancer cell line BT-474.Methods Inhibition of BT-474 cell proliferation at different concentrations of fulvestrant, trastuzumab and the two drugs combined was assessed using the WST-1 assay.Flow cytometry(FCM) was used to detect the cell apoptosis rates by Annexin-V/PI assay. Moreover, the effect fulvestrant and trastuzumab respectively and combinedly have on the proteins p-Akt and p-MAPK was detected by Western blot assay. Results The cell proliferation was increasingly inhibited by fulvestrant, trastuzumab or them combined when each group's drug concentration added, with a CIED50 of 0.466.When fulvestrant and trastuzumab combined, the cell apoptosis rates were distinctly increased(P<0.05).Furthermore, the level of proteins p-Akt and p-MAPK expressed in the cell BT-474 was raised by fulvestrant, but definitively reduced when fulvestrant combined with trastuzumab. Conclusion Fulvestrant synergizes trastuzumab if they combine when acing on the cell line BT-474, maybe because fulvestrant combined with trastuzumab increases the cell proliferation inhibition, promotes the cell apoptosis and restrains fulvestrant from enhancing the proteins p-Akt and p-MAPK expression.
Keywords：breast neoplasmBT-474fulvestranttrastuzumab
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 749-752 )